Cancer Vaccines
Supplemental Application for GARDASIL(R), Merck's Cervical Cancer Vaccine, Designated Priority Review by the U.S. FDA for Use in Women 27 through 45
Published in Vaccine Weekly, April 2nd, 2008
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted, and designated for priority review, the supplemental Biologics License Application (sBLA) for GARDASIL(R) (Human Papillomavirus Quadrivalent) (Types 6, 11, 16, 18) Vaccine, Recombinant) for the potential use in women aged 27 through 45. A priority designation is intended for products or indications that address unmet medical needs. Under the Prescription Drug User Fee Act, the FDA's goal is to review and act on 90 percent of BLAs designated as priority review within six months of receipt.
GARDASIL is currently indicated for girls and women nine through 26 years of age for the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2008-04-02)
More Articles from Vaccine Weekly
- Dengue Fever
Studies from National Heart, Lung, & Blood Institute provide new data on dengue fever - DNA Vaccines
Researchers at University of Pennsylvania, Medical Department target DNA vaccines - Genetics & Genomics
Findings from University of Oxford provide new insights into genetics & genomics - Influenza
New influenza research from Niigata University described - Influenza
Research reports on influenza from Z.Y. Chen and colleagues provide new insights - Influenza
Study data from D.A. Kaminski and colleagues update understanding of influenza - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
